The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
406
Change in NCP Volume from Baseline to Week 72
Time frame: Baseline to Week 72
Change in Low Attenuation Plaque Volume from Baseline to Week 72
Time frame: Baseline to Week 72
Change in Total Plaque Volume from Baseline to Week 72
Time frame: Baseline to Week 72
Change in Calcified Plaque Volume from Baseline to Week 72
Time frame: Baseline to Week 72
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Week 74
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bridgeport Hospital
Bridgeport, Connecticut, United States
RECRUITINGJacksonville Center for Clinical Research
Jacksonville, Florida, United States
RECRUITINGMidwest Heart and Vascular Specialists
Overland Park, Kansas, United States
RECRUITINGFlourish Bowie
Bowie, Maryland, United States
RECRUITINGMontefiore Medical Center - Bronx
Philadelphia, Pennsylvania, United States
RECRUITINGVital Heart and Vein
Humble, Texas, United States
RECRUITINGAdvara HeartCare Wesley
Auchenflower, Queensland, Australia
RECRUITINGUniversity of The Sunshine Coast Clinical Trials, Sippy Downs
Sippy Downs, Queensland, Australia
RECRUITINGAdvara HeartCare Leabrook
Leabrook, South Australia, Australia
RECRUITINGNorth York Diagnostic and Cardiac Centre
Vaughan, Ontario, Canada
RECRUITING...and 30 more locations